Drug profile

The FDA adverse-event record for Unspecified Glucosamine

21 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Glucosamine. Species, reactions, and outcomes follow.

#1776 of 2,679
by report volume (all drugs)
21
adverse-event reports
23.8%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Glucosamine ranks #1727 of 2679 by total reports (21). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1727
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Glucosamine has 21 reports now versus 20 in that prior snapshot: 1 more (5.0%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Glucosamine changes

Signature read: Unspecified Glucosamine's 23.8% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
5
Deaths Reported
23.8%
Death-coded share of reports

Active Ingredients

Unspecified Glucosamine

Administration Routes

OralUnknown

Species Affected

Dog 21

Most Affected Breeds

Shepherd Dog - German 3
Collie - Border 3
Chihuahua 2
Retriever - Golden 2
Crossbred Canine/dog 2
Catahoula Leopard Dog 1
Dog (unknown) 1
Siberian Husky 1
Terrier (unspecified) 1
Terrier - Bull - Staffordshire 1

Most Reported Reactions

Urinary incontinence 4
Itching 3
Death by euthanasia 3
Diarrhoea 3
Lethargy (see also Central nervous system depression in Neurological) 3
Lack of efficacy - NOS 3
Death 2
Skin lesion NOS 2
Chewing - pruritus (see also Oral cavity disorders) 2
Skin sore 2
Panting 2
Seizure NOS 2

Outcome Breakdown

Outcome Unknown
8 (38.1%)
Recovered/Normal
4 (19.0%)
Ongoing
4 (19.0%)
Euthanized
3 (14.3%)
Died
2 (9.5%)

Unspecified Glucosamine: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Glucosamine (#1776 of 2,679 by report volume); death-coded 23.8%. PlainBreed drug row · death-coded share stamp 23.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →